Steven Cohen's ATYR Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 37,278 shares of aTyr Pharma, Inc. (ATYR) worth $22,248, representing 0.00% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Steven Cohen has maintained this position in ATYR for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 37,278 shares. Largest reduction occurred in Q1 2025, reducing 2.04 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's aTyr Pharma (ATYR) Holding Value Over Time
Track share changes against reported price movement
Quarterly aTyr Pharma (ATYR) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +37,278 | New Buy | 37,278 | $0.60 |
| Q3 2025 | -988,677 | Sold Out | 0 | $0.00 |
| Q2 2025 | -1.86 M | Reduce 65.24% | 988,677 | $5.07 |
| Q1 2025 | -2.04 M | Reduce 41.76% | 2.84 M | $3.02 |
| Q4 2024 | +4.88 M | New Buy | 4.88 M | $3.62 |
Steven Cohen's aTyr Pharma Investment FAQs
Steven Cohen first purchased aTyr Pharma, Inc. (ATYR) in Q4 2024, acquiring 4,883,197 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held aTyr Pharma, Inc. (ATYR) for 5 quarters since Q4 2024.
Steven Cohen's largest addition to aTyr Pharma, Inc. (ATYR) was in Q4 2024, adding 4,883,197 shares worth $17.68 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 37,278 shares of aTyr Pharma, Inc. (ATYR), valued at approximately $22,248.
As of the Q2 2026 filing, aTyr Pharma, Inc. (ATYR) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in aTyr Pharma, Inc. (ATYR) was 4,883,197 shares, as reported at the end of Q4 2024.